Deutsche Bank upgraded Alvotech (ALVO) to Buy from Hold with a $14 price target The firm believes the company offers “scarcity value” in the biosimilar market, which “remains within its infancy.” Alvotech is well positioned to benefit from the sector’s opportunity, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALVO: